Why Relmada Therapeutics, Inc.’s (RLMD) Stock Is Down 5.70%
As of Friday, July 31, Relmada Therapeutics, Inc.’s RLMD share price has dipped by 5.70%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Commentary & Analysis
Why Relmada Therapeutics, Inc.’s (RLMD) Stock Is Down 6.44%
As of Thursday, July 16, Relmada Therapeutics, Inc.’s RLMD share price has dipped by 6.44%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Relmada Therapeutics, Inc.’s (RLMD) Stock Is Down 5.78%
As of Wednesday, July 01, Relmada Therapeutics, Inc.’s RLMD share price has dipped by 5.78%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Relmada Therapeutics, Inc.’s (RLMD) Stock Is Up 5.12%
As of Friday, June 26, Relmada Therapeutics, Inc.’s RLMD share price has surged by 5.12%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Relmada Therapeutics, Inc.’s (RLMD) Stock Is Up 5.04%
As of Wednesday, June 17, Relmada Therapeutics, Inc.’s RLMD share price has surged by 5.04%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | RLMD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $557.0 | $579.1 | 39% |
|
| Shares Out (Mil) | 86.6 | 43.0 | 60% |
|
| Institutional Ownership | 93.8% | 84.3% | 64% |
|
| Float (Mil) | 75.7 | 46.8 | 56% |
|
| Beta | 0.43 | 0.62 | 24% |
|
| Avg Daily Volume (000s) | 1,611 | 285 | 78% |
|
| Price Change (52-week) |
729.6% | 63.8% | 100% |
|
| Growth | RLMD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | 0.7% | (1.4%) | 40% |
|
| EPS (5yr) | 17.5% | 14.9% | 63 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 65.9% | (14.9%) | 96% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | RLMD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $272 | na |
|
| Net Income (TTM) (Mil) | ($59) | ($11) | 15% |
|
| EPS (TTM) | ($1.100) | ($0.500) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($43) | ($6) | 10% |
|
| Net Cash Flow (TTM) (Mil) | $9 | $4 | 56% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $7 | 0% |
|
| Enterprise Value (Q1) (Mil) | $522 | $522 | 35% |
|
| Valuation | RLMD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.54 | 2.73 | 60% |
|
| P/E | na | 20.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | RLMD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 65.9% | na |
|
| Net Margin | na | 0.7% | na |
|
| ROA | (44.8%) | (24.6%) | 13% |
|
| ROE | (48.8%) | (19.7%) | 16% |
|
| Liabilities to Assets | 7.1% | 35.5% | 4% |
|
| F-Score | 3 | 3 | 19% |
|
Relmada Therapeutics, Inc. did not pass any screens on 7/31/2026.
